MiMARK Diagnostics, S.L., member of CataloniaBio & HealthTech, has successfully raised €4.22 million as seed round stage. The substantial investment will drive the development of the company's groundbreaking gynaecological diagnostics solutions, with key EU participation from the EIC Accelerator (European Innovation Council) and private investors, including Clave Capital, Nara Capital, Namarel Ventures, and WA4STEAM investing in May this year, and CDTI Innvierte, Inveready (member of CataloniaBio & HealthTech too) and Canterbury Scientific, joining later on.
Marina Rigau, CEO and co-founder of MiMARK, expressed gratitude for the support received: "This seed funding represents a significant milestone for MiMARK and validates our commitment to improve gynaecological diagnostics. Thanks to this funding we will advance on bringing our first product to the market; an In Vitro Diagnostic for Endometrial Cancer. We are excited about the journey ahead and the positive impact our innovations will have on women's health."
The newly secured funds will be instrumental in advancing MiMARK Diagnostics' mission to transform gynaecological diagnostics, and especially to advance the first product to the market.
Future plans include the accelerating verification and clinical validation for WomEC; an IVD for endometrial cancer diagnosis. Also expanding research and development efforts to address other unmet clinical needs in gynecological health, with a focus on leveraging gynecological fluids as a source of biomarkers. A second target indication for the company is endometriosis diagnosis. And finally strengthening collaborations with leading institutions, healthcare professionals, and industry partners to further advance the field of gynecological diagnostics.
MiMARK Diagnostics, S.L. remains committed to improving women's health through innovation and scientific excellence.
Comments